ViiV pulls once-daily maraviroc submissions
This article was originally published in Scrip
Executive Summary
ViiV Healthcare, the HIV-focused joint venture between GlaxoSmithKline and Pfizer, has withdrawn its Type II Variation to the European Medicines Agency (EMA) and its supplemental new drug application (sNDA) to the US FDA for once-daily administration of Celsentri/Selzentry (maraviroc) tablets in treatment-experienced patients infected with only CCR5-tropic HIV-1.